glp-1 and fatty liver disease disease. Non-alcoholic fatty liver affects 25% of adults worldwide. It is directly linked to excess weight and insulin resistance. Left untreated, it can progress to cirrhosis and GLP-1 Fatty Liver MASH Approval:

The Great (Oral) GLP-1 Scare Why the Stevanato narrative is flawed This is not something that should take you by surprise because Ive talked about it in the past, but Stevanatos stock has been weak lately (maybe an understatement): This has happened despite the company (imho) receiving incrementally positive news over the past few months

In this case, gently remove the needle without forcing it and do not attempt to straighten or reuse it

Here's my lovely legume cheat sheet for your viewing and eating pleasure

Market Report Coverage and Key Metrics Market Dynamics Drivers Shift to Oral Formulations The shift to oral formulations is a main driver of the GLP-1 market because it directly removes patient barriers, simplifies daily routines, needle anxiety, and eliminates complex cold chain logistics

Although immediate weight loss may not be seen in the first week, consistent commitment to the program will support lasting, sustainable weight loss over time